Cancer

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This study tests whether adding tadalafil (a drug used for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. Ten adults with resectable cancer will receive tadalafil alone for two weeks, then combined with c…

This study compares a reduced dose of radiation therapy combined with the immunotherapy drug nivolumab against the standard treatment of full-dose radiation plus cisplatin for early-stage HPV-positive oropharyngeal cancer in non-smokers. About 384 participants are enrolled to see…

This study is for people with inflammatory breast cancer, a rare and aggressive type, who have already had chemotherapy and surgery. It tests whether adding the drug olaparib to standard radiation therapy helps keep the cancer from coming back. About 300 participants will be rand…

This phase 3 trial tests whether taking erlotinib (Tarceva) after surgery helps people with EGFR-mutant non-small cell lung cancer live longer and stay cancer-free longer. About 390 patients who had their lung cancer completely removed are randomly assigned to receive erlotinib p…

This phase III trial compares two first-line treatments for people with a specific genetic subtype of metastatic colorectal cancer (dMMR/MSI-H). One group receives the immunotherapy drug atezolizumab alone, while the other gets atezolizumab combined with chemotherapy (FOLFOX) and…

This phase 2 trial is testing a combination of two drugs—cabozantinib (a pill) and nivolumab (an infusion)—in 47 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The main goal is to see if the treatment can delay can…

This phase III trial tests whether adding the immunotherapy drug nivolumab after standard chemotherapy and radiation helps people with HPV-positive throat cancer live longer without the cancer growing. About 636 patients with intermediate-risk, locally advanced disease will eithe…

This study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …

This study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can completely eliminate advanced rectal cancer before surgery. About 31 adults with a specific genetic type (MSI-H/dMMR) of stage II or III rectal cancer wil…

This first-in-human study tests an experimental oral drug called IDRX-42 in 278 adults with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The main goals are to check safety, find the right dose, and see if the drug can shrink tu…

This study tests whether adding a targeted drug called ganitumab to standard chemotherapy helps people with newly diagnosed Ewing sarcoma that has spread. The trial includes 312 participants and aims to see if the combination improves survival without the cancer growing back. The…

This study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…

This study tests the safety of combining the targeted drug alectinib with chemotherapy in people who have had surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). The 11 participants received up to four cycles of the drug combo after their tumor w…

This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…

This phase II trial is testing whether combining the targeted drug trametinib with the chemotherapy docetaxel can shrink tumors in people with advanced KRAS-mutant non-small cell lung cancer. The study enrolls 60 patients whose cancer has worsened after one or two prior treatment…

This study tests whether two immunotherapy drugs, ipilimumab and nivolumab, can shrink or slow the growth of recurrent high-grade gliomas (brain tumors) that have a high number of genetic mutations. About 37 adults with recurrent WHO grade 4 glioma will receive these drugs. The g…

This study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…

This phase 2 trial tests a weekly combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy pembrolizumab in 31 patients with metastatic head and neck cancer who cannot receive the standard drug 5-fluorouracil. The goal is to see if this regimen sh…

This large phase 3 trial studied over 10,000 women with early-stage, hormone-receptor-positive breast cancer that hasn't spread to lymph nodes. It used the Oncotype DX test to assign women to hormone therapy alone or hormone therapy plus chemotherapy based on their recurrence sco…

This phase 2 trial tests a combination of two drugs, lenvatinib and paclitaxel, in 51 adults with advanced biliary tract cancer that has worsened after standard gemcitabine treatment. The goal is to see if the combo can shrink tumors and slow the disease. Participants take lenvat…

This phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…

This phase III trial tests whether adding the immunotherapy drug nivolumab after standard combined modality therapy (chemo and radiation) can improve outcomes for patients with high-risk stage IIB-IIIC anal cancer. About 344 participants will receive nivolumab or a placebo. The m…

This phase II trial tests pembrolizumab, an immunotherapy drug, in 57 patients with desmoplastic melanoma, a rare skin cancer. The drug helps the immune system attack cancer cells. The study includes patients whose tumors can be surgically removed (cohort A) and those whose canno…

This phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread…

This phase 2 trial tests whether adding pembrolizumab (an immunotherapy) to olaparib (a targeted therapy) works better than olaparib alone for controlling metastatic pancreatic cancer in people with inherited BRCA1 or BRCA2 mutations. About 88 participants will receive either the…

This early-stage trial is testing a new drug called JS207 in about 98 people with advanced cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also loo…

This phase 2 trial tests two drugs, erlotinib and cabozantinib, given alone or together in 125 patients with advanced non-small cell lung cancer that does not have a common EGFR mutation. The goal is to see if the combination works better than either drug alone to slow cancer gro…

This phase II trial is testing two different drug combinations for people with metastatic pancreatic cancer that has spread. One group gets a standard chemo plus S-1 and leucovorin; the other gets standard chemo plus oxaliplatin. The goal is to see which combo works better at shr…

This early-phase trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (cisplatin and pemetrexed) before and after surgery can help people with resectable pleural mesothelioma. The study includes 28 participants with stage I-III disease. The…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This phase 3 trial tests whether adding the drug triapine to standard radiation and cisplatin improves survival in women with advanced cervical or vaginal cancer. About 450 participants receive either standard treatment or standard treatment plus triapine. The study aims to see i…

This study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…

This study tests whether adding the immunotherapy drug pembrolizumab to standard radiation therapy can better prevent cancer recurrence in people with newly diagnosed, early-stage endometrial cancer that has a specific genetic feature (mismatch repair deficiency). About 164 parti…

This phase 3 trial studies whether taking lenalidomide (Revlimid) after an autologous stem cell transplant can delay the return of multiple myeloma compared to a placebo. About 460 patients with active myeloma who had a stem cell transplant are involved. The main goal is to see h…

This study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like…

This study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in adults with multiple myeloma that has come back or is not responding to prior treatments. The goal is to see if this mix can shrink or control the cancer. The trial enrolled 5 participant…

This study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…

This study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …

This study tests whether the drug afatinib can shrink tumors in people with advanced cutaneous squamous cell carcinoma (a type of skin cancer) that cannot be treated with surgery or radiation. About 25 adults with adequate organ function will receive afatinib, and researchers wil…

This early-phase trial is testing whether combining the targeted drug olaparib, the immunotherapy durvalumab, and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be surgically removed. The study enrolls 18 participants who have already rec…

This study tests if a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy works better than the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-small cell lung cancer that has spread. The trial is for patien…

This phase 2 study tests the drug selinexor against standard treatments in 112 people with myelofibrosis who have already tried JAK inhibitors. The main goal is to see if selinexor can shrink the spleen and improve symptoms. Participants are randomly assigned to receive either se…

This phase II trial tests a shorter, higher-dose radiation therapy followed by the immunotherapy drug atezolizumab in 47 patients with stage II or III non-small cell lung cancer who have borderline health. The goal is to see if this approach is safe and effective for people who c…

This early-phase study tests a new drug called AB680, combined with immunotherapy (zimberelimab) and two chemotherapy drugs (nab-paclitaxel and gemcitabine), in people with advanced pancreatic cancer that has spread. The main goals are to check safety and find the right dose. Abo…

This phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…

This phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help prevent cancer from coming back in people with stage III colon cancer that has a specific DNA repair defect (dMMR). About 712 participants will receive either chemo …

This phase III trial tests whether proton radiation therapy works better than standard photon (X-ray) radiation for people with liver cancer that cannot be removed by surgery or has come back. The study involves 115 participants and compares overall survival and side effects. Pro…

This phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced (stage III or IV) or recurrent endometrial cancer. About 800 participants received either the combo or chemo alone. The …

This phase 3 trial tests whether the immunotherapy drug ipilimumab is better than high-dose interferon alfa-2b at preventing melanoma from coming back in patients whose cancer was removed by surgery. Over 1,600 people with high-risk stage III or IV melanoma took part. The study m…

This study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…

This study tests whether olaparib (a targeted drug) alone or combined with cediranib (which blocks tumor blood vessels) works better than standard platinum chemo for women whose ovarian, fallopian tube, or peritoneal cancer has returned after initial treatment. About 579 particip…

This early-phase trial tests a new drug called NT219 combined with either pembrolizumab or cetuximab in 29 adults with head and neck cancer that has returned or spread. The goal is to see if the combination shrinks tumors. Participants receive weekly NT219 plus one of the other d…

This study is testing whether adding a DNA vaccine (pTVG-AR) and immune checkpoint blockers (nivolumab or cemiplimab) to standard hormone therapy can improve outcomes for men with newly diagnosed, high-risk prostate cancer. About 60 participants will receive different combination…

This trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…

This study looks at how prostate cancer treatments, especially hormone therapy, affect heart health. It includes two parts: one that follows men over time to track heart problems, and another that tests whether a program of healthy eating, exercise, smoking cessation, and medicat…

This Phase 2 study tests whether adding another drug (ceralasertib or adavosertib) to the standard drug olaparib works better than olaparib alone for people with metastatic triple-negative breast cancer. The trial includes 273 adults whose cancer has specific genetic changes. One…

This phase III trial studies whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage 3 non-small cell lung cancer that cannot be surgically removed. About 660 participants will receive either chemoradiation plus durvaluma…

This phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…

This phase III trial is testing the immunotherapy drug atezolizumab (Tecentriq) in 60 people with advanced non-small cell lung cancer that has high PD-L1 levels and has not been treated before. Participants receive the drug every three weeks. The study aims to see if it helps the…

This study looks at how well oral vinorelbine, a chemotherapy pill, works in women with advanced breast cancer. It includes women who have already taken the drug or are starting it now. Researchers track how long the cancer stays under control and how patients feel during treatme…

This program provides tazemetostat, an experimental drug taken as a pill twice daily, to adults with advanced epithelioid sarcoma—a rare cancer—who have no satisfactory alternative treatments. It is designed for people who cannot join other clinical studies or access the drug thr…

This phase 2 trial is testing a shorter course of high-dose radiation (hypofractionated radiotherapy) for soft tissue sarcoma. The goal is to see if this approach can control the tumor for at least two years while reducing damage to nearby healthy tissue. About 48 adults with ino…

This Phase 3 trial tests whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent bladder cancer from returning after surgery. About 739 patients with muscle-invasive or locally advanced urothelial cancer are randomly assigned to receive pembrolizumab or just be o…

This Phase 2 trial tests a combination of pembrolizumab (Keytruda) and quavonlimab against other drug combos in 302 people with stage IV colorectal cancer that has a specific genetic feature (MSI-H or dMMR). The goal is to see if the new combo shrinks tumors better and for longer…

This study tests a combination of two drugs, sacituzumab govitecan and berzosertib, in adults with small cell lung cancer or cancers that have stopped responding to PARP inhibitors. The goal is to find a safe dose and see if the combo can shrink tumors. Participants receive the d…

This Phase II trial tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than chemotherapy plus just one immunotherapy drug in people with advanced biliary tract cancer. The study will enroll 76 adults whose can…

This phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…

This study compares two drug combinations—melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR)—in 306 newly diagnosed multiple myeloma patients who cannot have high-dose therapy. The goal is to see which combination better delays cance…

This study follows 165 children who previously took dabrafenib and/or trametinib for certain brain tumors. Researchers want to see if these drugs are safe over the long term and how they affect growth. The children continue their treatment and are monitored for side effects and d…

This phase III trial compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive, HER2-negative early breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming ba…

This study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…

This study is for people with advanced non-small cell lung cancer that does not have the PD-L1 marker, making it harder to treat with immunotherapy alone. The trial compares standard immunotherapy (with or without chemotherapy) to the same treatment plus radiation therapy. The go…

This phase III trial compares two sequences of treatment for advanced melanoma with a BRAF mutation. One group starts with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib) if needed; the other group starts with targeted therapy the…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This phase 3 trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin and paclitaxel) helps people with metastatic anal cancer live longer without their disease getting worse. About 205 adults with inoperable or recurrent anal cancer …

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This phase II trial tests whether adding a growth factor (GM-CSF) to the immunotherapy drug ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that cannot be surgically removed are randomly assigned to get ipilimumab alone…

This study tests whether adding a drug called sargramostim to the standard immunotherapy combination of nivolumab and ipilimumab helps people with advanced melanoma live longer. About 600 patients with stage III or IV melanoma that cannot be surgically removed are participating. …

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This study tests whether adding the immunotherapy drug nivolumab after surgery and chemotherapy helps prevent non-small cell lung cancer from coming back. About 900 adults with stage IB to IIIA lung cancer who had their tumor completely removed are participating. The goal is to s…

This phase 2 trial explores whether adding low-dose radiotherapy and an immunotherapy drug (retlirafusp alfa) to standard chemotherapy before surgery can improve outcomes for people with a type of esophageal cancer that has spread locally but can still be removed. The study enrol…

This study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective optio…

This Phase 3 trial is testing whether adding an experimental drug called quemliclustat to standard chemotherapy (nab-paclitaxel and gemcitabine) helps people with metastatic pancreatic cancer live longer. About 610 participants who have not yet received treatment for their advanc…

This study compares two radiation methods—proton beam and photon beam (IMRT)—in 120 people with slow-growing brain tumors (IDH-mutant gliomas). The goal is to see which better preserves memory and thinking over time. Participants are randomly assigned to one type of radiation and…

This early-stage study tests a new drug called JSB462 (Luxdegalutamide) in 15 Japanese men whose prostate cancer has spread to other parts of the body. The main goal is to check the drug's safety and how the body processes it. Participants take the drug once daily with food.

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This phase II trial tests the drug nivolumab (Opdivo) in 26 women with cervical cancer that has persisted, returned, or spread despite prior treatment. Nivolumab is an immunotherapy that helps the body's immune cells recognize and attack cancer. The study measures how many patien…

This Phase 3 trial is testing whether adding the drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that lacks a specific genetic mutation (FLT3-ITD). About 700 participants will receive either quizartinib or a placebo alongsi…

This study is for people with non-small cell lung cancer who have had chemotherapy and surgery. It tests whether adding a drug called AZD6738 to the immunotherapy drug durvalumab can help keep the cancer from coming back longer than durvalumab alone. About 630 adults with stage I…

This phase 2 trial compares two standard CML drugs—imatinib (Gleevec) at two different doses and dasatinib (Sprycel)—in 406 newly diagnosed patients with chronic phase CML. The main goal is to see which treatment leads to the best molecular response after 12 months, meaning a ver…

This phase 2 trial tests whether adding tuvusertib (a drug that blocks a DNA repair enzyme) to avelumab (an immunotherapy) can slow cancer growth in people with advanced Merkel cell cancer that didn't respond to prior treatment. About 50 participants will receive either the combi…

This study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…

This phase III trial is testing two different treatment sequences for people with advanced non-squamous non-small cell lung cancer. One group starts with the immunotherapy drug pembrolizumab alone, then adds chemotherapy only if the cancer progresses. The other group receives pem…

This study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with advanced esophageal or stomach-junction cancer live longer without their cancer growing. About 94 adults whose cancer has spread and who have already tried one treatmen…

This early-stage trial tests a treatment called CG0070, a virus-based therapy given directly into the bladder, after standard surgery for intermediate-risk non-muscle invasive bladder cancer. About 20 participants will receive the treatment to see if it is safe and helps prevent …

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…

This phase III trial compares the drug pembrolizumab (MK-3475) to the current standard treatments—high-dose interferon or ipilimumab—in 1,301 patients with high-risk melanoma that has been surgically removed. The goal is to see if pembrolizumab is better at preventing the cancer …

This study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…

This study tests a precise radiation technique called adaptive SBRT for men with high-risk or unfavorable intermediate-risk prostate cancer. The treatment targets the prostate and pelvic lymph nodes while giving an extra radiation boost to tumor spots seen on MRI. The goal is to …

This study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 participants will receive either the new combination …

This phase 2 trial tests whether adding petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in adults with metastatic non-small cell lung cancer. About 180 participants will receive the combination as their first treatment. The study focuses on how many pat…

This phase 3 trial tests whether adding the immune-boosting drug nivolumab before and after kidney cancer surgery can prevent the cancer from coming back. About 819 patients with localized kidney cancer are randomly assigned to receive either surgery alone or surgery plus nivolum…

This Phase III trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer that hasn't spread. About 475 participants receive either chemoradiotherapy alone or with atezolizumab. The main goal is to…

This study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) works better than hormone therapy alone for people with recurrent or metastatic endometrioid endometrial cancer. About 96 participants with grade 1 or 2 cancer will receive either…

This phase 3 trial tests whether iberdomide is better than lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays cancer progression longer. The st…

This phase III trial studies whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with limited stage small cell lung cancer live longer. About 544 participants receive either chemoradiation alone or chemoradiation plus atezolizumab. The main …

This phase II trial tests whether adding pembrolizumab (Keytruda) and trastuzumab (Ontruzant) to standard FLOT chemotherapy, given before and after surgery, can improve outcomes for people with HER2-positive esophagogastric adenocarcinoma. Participants receive the drug combinatio…

This phase 2 trial compares two ways of taking the targeted drugs dabrafenib and trametinib for advanced BRAF-mutant melanoma: continuously versus with planned breaks. About 280 people with stage III or IV melanoma that cannot be surgically removed are participating. The goal is …

This study compares the standard drug azacitidine alone versus azacitidine combined with either lenalidomide or vorinostat in 282 patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if any combination improves re…

This study tests an experimental oral drug called LY3410738 in people with advanced blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) that have specific IDH1 or IDH2 gene mutations. The drug is designed to block the mutated IDH proteins that he…

This study tests a new drug called JDQ443 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation) and does not respond well to standard treatments. The drug is taken as a pill and aims to shrink or control the cancer. About 95 participants will…

This study tests whether adding fianlimab to the standard immunotherapy cemiplimab helps people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 850 patients will receive either the drug combo or cemiplimab alone. Researchers will mea…

This phase II trial studies whether giving the immunotherapy drug pembrolizumab both before and after surgery is more effective than giving it only after surgery for patients with stage III-IV high-risk melanoma. About 313 participants will be randomly assigned to one of two trea…

This study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…

This phase 2 trial is testing two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with rare INI1-negative cancers that have come back or not responded to treatment. The study aims to see if the combination can shrink tumors or slow disease progression.…

This Phase 3 trial compares the drug niraparib to the standard chemo temozolomide in 450 adults with newly diagnosed, aggressive glioblastoma that has a specific genetic marker (MGMT unmethylated). Participants take the assigned drug daily during radiation, then continue until th…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This early study tests an oral drug called BTX-A51 in 24 people with advanced liposarcoma (a type of fat tissue cancer) that has spread or come back. The main goal is to see if the drug is safe and tolerable at different doses. It focuses on specific genetic subtypes: MDM2-amplif…

This phase II trial is testing whether adding chemotherapy to the immunotherapy drug atezolizumab works better than atezolizumab alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The study involves 240 adults with localiz…

This phase 3 trial tests a new drug, belantamab mafodotin, against a standard treatment (pomalidomide plus dexamethasone) in 325 people with multiple myeloma that has returned or stopped responding to prior therapy. The main goal is to see if the new drug delays cancer progressio…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…

This study tests whether a personalized, two-phase radiation therapy approach can better control glioblastoma, an aggressive brain cancer. The treatment adapts the radiation plan based on tumor changes during therapy, potentially targeting the tumor more precisely while sparing h…

This trial tests whether a new type of MRI, called MR fingerprinting, can better show where a glioblastoma (an aggressive brain tumor) has spread compared to standard MRI. The goal is to help surgeons remove more of the tumor safely. The study involves adults with suspected gliob…

This study tests whether combining two drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based chemo. About 582 women will be randomly assign…

This study tests a mix of immune-boosting drugs, natural killer cells, and a device that sends low-intensity electric fields to the brain for people with glioblastoma that has come back after initial treatment. The trial has two parts: first, everyone gets the drug combo; second,…

This study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This study is for women with a low-risk type of breast cancer that has spread to nearby lymph nodes or is T3N0. It compares standard care (which includes radiation to the lymph node area) against skipping that extra radiation. The goal is to see if avoiding regional radiation wor…

This study tests a combination of three treatments—immunotherapy (tislelizumab), targeted therapy (afatinib), and a modified herpes virus (lysogenic HSV)—given before surgery for head and neck squamous cell carcinoma. The goal is to see if this approach safely shrinks tumors and …

This pilot study is testing whether combining a modified Atkins diet (low-carb, high-protein) with a 12-week fitness program can improve quality of life and physical function in 15 people with malignant glioma. Participants will follow the diet and attend two supervised exercise …

This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…

This early-phase trial tests whether adding bevacizumab to brigatinib can help people with ALK-positive non-small cell lung cancer whose disease has worsened on previous ALK-targeted therapy. The study enrolls just 5 patients and focuses on safety, side effects, and finding the b…

This study tests the drug ruxolitinib (Jakafi) in 29 people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if the drug can improve blood counts, shrink the cancer, or delay its turning into a more aggressive leukemia. Researchers are also che…

This phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…

This study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…

This phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …

This trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…

This phase 2 trial tests whether adding galeterone to standard chemotherapy (gemcitabine) can shrink tumors or slow disease in people with advanced pancreatic cancer that has not responded to prior treatments. The study enrolls about 15 adults with metastatic disease who have alr…

This study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …

This study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that t…

This study is for people with a specific type of lung cancer (non-squamous non-small cell) that has a KRAS G12C mutation and can be removed with surgery. It tests whether giving a targeted drug (sotorasib) plus standard chemotherapy before surgery can shrink the tumor more than c…

This early-phase trial tests whether adding an immune-boosting drug (aldesleukin) to standard chemotherapy and another immunotherapy (nivolumab) can help control stomach cancer that has spread to the lining of the abdomen. About 15 adults with this advanced cancer will receive th…

This early-stage trial is testing a new drug called AOH1996 in 12 adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The drug works by blocking a protein that helps cancer cells grow and repair themselves. The main goals are to fi…

This study monitors 453 patients with advanced thyroid cancer that cannot be removed by surgery and does not respond to radioactive iodine. All patients are taking the drug sorafenib (Nexavar) as part of their normal care. Researchers are tracking side effects and how long patien…

This phase 1 trial is testing a combination of total marrow and lymphoid irradiation (TMLI) plus two chemotherapy drugs, fludarabine and melphalan, given before a donor stem cell transplant. The goal is to find the safest dose of radiation that can kill cancer cells while prepari…

This early-phase trial tests a new immune cell therapy called CS1-CAR T cells for people with multiple myeloma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, engineering them in a lab to recognize and attack myeloma cel…

This early-stage trial tests a new type of CAR T-cell therapy designed to target a protein called MMP2 found on glioblastoma cells. The treatment uses a scorpion toxin fragment (chlorotoxin) to help the immune cells find and attack the tumor. Nineteen patients with recurrent or p…

This phase 2/3 trial is testing whether adding two immunotherapy drugs (cobolimab and dostarlimab) to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. The study includes about 758 participants whose cancer has worsened after pri…

This study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe …

This phase 2 trial tests whether giving hormone therapy before prostate surgery helps men with high-risk prostate cancer recover erectile function better. About 90 men will receive either apalutamide alone or a combination of apalutamide, abiraterone, GnRH agonist, and prednisone…

This early-phase study tests whether giving multiple doses of a special virus carried by neural stem cells is safe and possible for people with newly diagnosed high-grade glioma. Participants receive the therapy directly into the brain before, during, and after standard radiation…

This phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will rec…

This trial investigates a new type of immunotherapy called CAR T-cell therapy that targets two proteins, CD19 and CD22, found on B-cell leukemia cells. The therapy is given along with chemotherapy to children and young adults whose leukemia has come back or has not responded to s…

This trial investigates whether adding metformin, a common diabetes drug, to the immunotherapy pembrolizumab (Keytruda) can improve treatment for people with advanced melanoma. The study focuses on reversing metabolic problems inside tumors that may weaken immune cells. Participa…

This phase 2 trial is testing whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. The study includes 142 participants whose tumors are considered removable or…

This early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…

This trial investigates whether combining atezolizumab (a drug that boosts the immune system) with bevacizumab (a drug that blocks blood vessel growth) can shrink tumors in people with advanced melanoma that cannot be removed by surgery or has spread. The study focuses on patient…

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures ho…

This phase 3 trial tests whether adding two immunotherapy drugs—pembrolizumab and enfortumab vedotin—before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. The study includes patients who cannot take o…

This phase 3 trial compares a new drug, SHR-A1811, to the standard treatment T-DM1 in women with HER2-positive breast cancer who still have cancer cells after initial therapy. The goal is to see if SHR-A1811 can better prevent the cancer from coming back. Participants receive eit…

This early-phase trial is testing whether the immunotherapy drug nivolumab can help people with melanoma or lung cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). The drug is given both through a vein and directly into the spinal fluid via a l…

This phase 2 trial tests a combination of three drugs—daratumumab, a KRAS vaccine, and nivolumab—in people with advanced pancreatic cancer or non-small cell lung cancer that has not responded to prior treatment. The goal is to see if the combination can shrink tumors or slow canc…

This Phase III trial tests whether a modified short-course radiation that spares nearby lymph nodes, combined with chemotherapy (CAPOX) and the immunotherapy drug tislelizumab, works better than standard radiation plus chemotherapy for people with a certain type of rectal cancer …

This study tests a new drug called BNT327, given with chemotherapy, for people with advanced triple-negative breast cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 83 adults will take part, and the study is currently active but not …

This study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study tests whether adding two experimental drugs (LBL-007 and tislelizumab) to standard maintenance therapy can help control advanced colorectal cancer that has not spread widely. About 113 adults with unresectable or metastatic colorectal cancer will receive either the new…

This early-stage trial tests an experimental drug called SHR-1316, given as a shot under the skin, together with standard chemotherapy (carboplatin and etoposide) in people with extensive-stage small cell lung cancer who have not had prior treatment. The study looks at how the dr…

This study tests whether a new drug called zanidatamab, combined with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for advanced HER2-positive stomach and esophageal cancers. About 920 adults whose cancer has spread or ca…

This study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for…

This early-phase trial tests whether injecting special immune cells (natural killer cells) directly into skin cancer tumors can safely kill cancer cells. The study compares two types of donor NK cells—standard ones and ones engineered to be more potent—in 40 patients with basal o…

This pilot trial investigates whether hydroxychloroquine (a malaria drug) and everolimus (an immune-suppressing drug), taken alone or together, can help prevent breast cancer from returning in high-risk patients. The study enrolls people who have completed primary treatment for s…

This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to seek out and destroy cancer cells that have a specific marker called PSMA. The trial will check…

This trial tests whether giving a lower dose of radiation in just two sessions can reduce urinary side effects for men with intermediate-risk prostate cancer. All participants receive radiation on an MR-Linac, a machine that combines MRI imaging with radiotherapy for precise targ…

This phase 2 trial tests whether giving radiation once a day for five days (instead of every other day) can keep the breast looking good after treatment. It includes 48 women aged 40 or older with low-risk, hormone-sensitive breast cancer. The goal is to see if this shorter sched…

This study is for people with HER2-positive stage II to IIIa breast cancer whose tumors completely disappear after initial chemotherapy and targeted therapy before surgery. The goal is to see if using fewer chemotherapy drugs after surgery can still keep the cancer from coming ba…

This phase 2 trial tests whether giving chemotherapy directly into the eye (subconjunctival carboplatin) along with systemic topotecan can shrink advanced retinoblastoma tumors in children with disease in both eyes. The goal is to preserve the eye and vision, avoiding removal. Pa…

This Phase 3 trial tests whether adding ivosidenib (a targeted pill) to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 146 participants receive either the combo or a placebo plus azacitidin…

This early-phase trial tests whether adding an experimental drug called berzosertib to standard chemotherapy (carboplatin and gemcitabine) can better treat ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 adults with platinum-sensi…

This study tests whether giving a higher radiation dose to a brain area called the subventricular zone (where stem cells live) can delay glioblastoma from coming back. About 60 adults with newly diagnosed glioblastoma will receive standard radiation and chemo, but half will get e…

This early-phase trial tests a new drug called Peposertib, combined with radiation and chemotherapy, for people with a hard-to-treat type of brain cancer called glioblastoma. The study aims to find the best dose and check safety in 29 participants. If it works, the drug may help …

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests whether a higher dose of proton radiation, focused on tumors seen on MRI, can better control high-risk prostate cancer. About 100 participants will receive radiation over 8-9 weeks, plus hormone therapy for 18 months. The goal is to lower the chance of cancer ret…

This study compares two types of radiation therapy for men with favorable or low-tier intermediate risk prostate cancer: low dose rate (LDR) brachytherapy, which uses permanent radioactive seeds, and high dose rate (HDR) brachytherapy, which uses temporary radioactive material. T…

This phase 3 trial tests whether adding darolutamide to standard hormone therapy (ADT) after prostate removal surgery can better prevent cancer from spreading in men with high-risk prostate cancer. The study enrolls 27 men who had their prostate removed and are at highest risk of…

This trial investigates whether less invasive treatments can save the rectum in people with early-stage rectal cancer. Participants receive either standard surgery (removing part of the rectum) or one of two organ-sparing approaches: short-course radiotherapy or chemoradiation (c…

This phase 3 trial tests whether adding lurbinectedin to atezolizumab as maintenance therapy helps people with extensive-stage small-cell lung cancer live longer without the disease worsening. Participants first receive standard induction chemo-immunotherapy, then those with stab…

This Phase II trial is testing whether a combination of two chemotherapy drugs, doxorubicin and trabectedin, can help prevent uterine leiomyosarcoma from coming back after surgery. The study enrolls 48 patients with high-risk, early-stage disease who have had their tumor fully re…

This phase 3 trial tests whether SB27, a proposed biosimilar to the cancer drug Keytruda, works as well as the original in people with advanced non-squamous non-small cell lung cancer. About 555 participants will receive either SB27 or Keytruda plus chemotherapy every 3 weeks. Th…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This trial tests a vaccine called LabVax 3(22)-23, designed to help the immune system recognize and attack a protein called labyrinthin found on adenocarcinoma tumor cells. The study includes adults with advanced or metastatic adenocarcinoma and will evaluate the vaccine alone or…

This phase 2 trial tests whether adding berzosertib to standard chemotherapy (topotecan) helps people with relapsed small-cell lung cancer live longer without their cancer growing. About 104 participants will receive either the combo or topotecan alone. The goal is to see if berz…

This study tests a combination of two drugs—cabozantinib (a targeted therapy) and 177Lu-PSMA-617 (a radioactive drug)—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose and see if the combination can slow cancer gr…

This trial investigates the best way to treat children with acute myeloid leukaemia (AML) by comparing different chemotherapy drugs and doses. It tests whether adding up to three doses of the targeted drug gemtuzumab ozogamicin to standard chemo is safe and effective. The study a…

This phase 3 trial compares two types of stem cell transplants for children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). One uses a half-matched family donor (haploidentical), the other a fully matched unrelated donor. The goal is to see w…

This study tests whether combining three different antibodies—BI 770371, pembrolizumab, and cetuximab—can shrink tumors in people with head and neck cancer that has spread or come back. About 91 adults are randomly assigned to one of three treatment groups. The goal is to see if …

This early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…

This study looks at whether adding a precise type of radiation (SBRT) to intermittent hormone therapy can better control prostate cancer that has spread to a few places in the body. The trial involves 60 men whose cancer was detected by a special PET scan but not by standard scan…

This Phase II trial tests a new drug, JSB462 (luxdegalutamide), combined with a radioactive therapy (Pluvicto) in 138 men with PSMA-positive metastatic castration-resistant prostate cancer that has progressed after prior treatments. The study aims to see if the combination works …

This trial tests a combination of donor immune cells (targeting a common virus) and the drug pembrolizumab (Keytruda) in 58 people with glioblastoma, an aggressive brain cancer. The goal is to see if this approach can shrink tumors and help patients live longer. The study has two…

This phase 3 trial tests whether a new drug combination (MK-7684A) plus chemoradiotherapy helps people with stage III non-small cell lung cancer live longer than the current standard treatment. About 611 participants will receive either the new combo or durvalumab. The study is a…

This phase II trial compares two chemotherapy regimens in 176 older patients with metastatic pancreatic cancer. One group receives gemcitabine plus nab-paclitaxel, the other receives fluorouracil, leucovorin, and liposomal irinotecan. The goal is to see which combination helps pa…

This phase II trial tested whether adding bevacizumab to osimertinib works better than osimertinib alone for patients with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. Only 5 patients were enrolled. The goal was to see if t…

This phase 3 trial tests whether adding the targeted drug zipalertinib to standard chemotherapy can delay or prevent lung cancer from returning in people with early-stage non-small cell lung cancer (stages IB to IIIA) who have uncommon EGFR mutations. After complete tumor removal…

This early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting …

This phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…

This study tests a combination of laser heat therapy (LITT) and the immunotherapy drug pembrolizumab in 32 adults with recurrent glioblastoma, an aggressive brain cancer. The laser heats and destroys hard-to-reach tumors, while pembrolizumab helps the immune system fight cancer c…

This phase II trial is testing whether a combination of two targeted drugs, trastuzumab and pertuzumab, can shrink tumors in patients with HER2-amplified cancers that are not breast, stomach, or colorectal. The drugs block signals that make cancer cells grow and help the immune s…

This phase 2 trial tests the drug pembrolizumab in 101 adults with cancer that has spread to the brain or spinal cord. The goal is to see if the drug can shrink or stabilize these tumors. Participants receive pembrolizumab along with standard imaging and sometimes radiation. The …

This study follows over 800 men with non-metastatic castration-resistant prostate cancer who are already taking darolutamide as part of their normal care. Researchers are tracking side effects and how well the drug controls the cancer in real-world conditions, outside of a strict…

This study is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to other cancer treatments can help men with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread and no longer responds to hormone therapy. About 1,…

This phase 3 study tests whether two targeted cancer pills, dabrafenib and trametinib, can help people with advanced thyroid cancer that has a specific gene change (BRAF V600E) and no longer responds to radioactive iodine. About 153 adults who have already tried one or two other …

This phase 3 trial tests whether a daily inhaler containing two bronchodilators (vilanterol and umeclidinium) can help preserve lung function and improve quality of life in people with mild-to-moderate COPD who are undergoing lung cancer surgery. About 204 participants will use t…

This study compares two versions of the drug teclistamab—one made with the current process and one with a new process—in 108 people with multiple myeloma that has come back or not responded to treatment. The main goal is to see if the body absorbs and handles both versions the sa…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see h…

This phase 3 trial tests whether treatment for high-risk prostate cancer can be personalized based on a patient's genetic risk score. For those with a low genetic risk, a shorter course of hormone therapy plus radiation may be as effective as the standard 24-month treatment, with…

This Phase 3 trial tests whether the oral drug zongertinib can slow cancer growth better than standard chemotherapy plus immunotherapy in people with advanced HER2-mutant non-small cell lung cancer. About 428 adults who have not had prior treatment for advanced disease will be ra…

This study tests whether adding three drugs (vincristine, irinotecan, and regorafenib) to standard chemotherapy can help people with Ewing sarcoma that has spread. About 437 participants will receive either the new combo or standard treatment. The goal is to see if the new approa…

This early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …

This phase 2 trial tests the safety and effectiveness of avelumab, an immunotherapy drug, in people with thymoma or thymic carcinoma that has progressed after platinum-based chemotherapy. About 56 participants will receive avelumab intravenously every two weeks. The study aims to…

This study tests whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel) can shrink or slow the growth of advanced solid tumors that have specific changes in the PTEN or AKT genes. About 33 adults whose cancer has spread or cannot be removed by surgery …

This early-phase trial tests whether giving chemoradiation plus the immunotherapy drug pembrolizumab, followed by pembrolizumab and lenvatinib before surgery, can kill more cancer cells in people with esophageal or gastroesophageal junction cancer that hasn't spread. The study in…

This study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with an antibody called ezabenlimab. The goal is to find a safe dose and see if the combination ca…

This Phase 2 trial tests whether the oral drug gilteritinib works better than midostaurin for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-mutated AML). All 181 participants also receive standard chemotherapy. The goal is to see which drug leads to more …

This study tests a combination of two drugs—cetuximab and interleukin-12—in people with advanced head and neck cancer that cannot be removed by surgery or has spread. The goal is to find the best dose and see if the combination can shrink tumors. Twenty-three participants are enr…

This study tests whether the drug olaparib, given before surgery, can shrink tumors in women with recurrent ovarian cancer that has come back after at least 6 months. About 71 participants will receive either olaparib or standard chemotherapy before surgery. Researchers will meas…

This phase 3 trial is testing a drug called ONCOFID-P-B for people with a type of bladder cancer that hasn't responded to standard BCG therapy. The drug is given directly into the bladder weekly for 12 weeks, then monthly for a year if it works. The goal is to see if it can contr…

This study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …

This phase 2 trial investigates whether adding the targeted drug palbociclib to standard endocrine therapy (letrozole or tamoxifen) improves tumor shrinkage before surgery in people with hormone receptor positive, HER2 negative breast cancer. The study includes both invasive lobu…

This phase 2 trial tests a drug called VK-2019 in 13 patients with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has returned or spread and has no standard treatment. VK-2019 works by blocking a key viral protein, EBNA1, which the virus needs to survive. The main g…

This phase II trial tests whether combining the immunotherapy drug durvalumab (Imfinzi) with radiation therapy can effectively treat intermediate-risk head and neck cancer after surgery, while causing fewer serious side effects than the standard cisplatin-based chemo-radiation. T…

This study tests whether adding the immune-boosting drug Sipuleucel-T (Provenge) to standard hormone therapy can help men with advanced prostate cancer that is no longer responding to hormones alone. The trial involves 26 participants who will receive either Sipuleucel-T alone or…

This Phase 3 study tests whether a new drug, inavolisib, combined with fulvestrant works better than the current standard alpelisib plus fulvestrant for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). The trial enrolled …

This phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …

This early-phase trial tests whether adding the experimental drug binimetinib to the immunotherapy pembrolizumab (Keytruda) helps people with advanced non-small cell lung cancer. The study includes 40 participants whose tumors have high PD-L1 levels. Researchers are looking at sa…

This study tests a new combination of drugs (Dara-SVD) for people with high-risk newly diagnosed multiple myeloma. It compares this new combo to the current standard treatment. The goal is to see if the new approach leads to better cancer control. About 70 participants will take …

This phase 2 trial tests whether giving patients with hard-to-treat acute myeloid leukemia (AML) a special type of immune cell—called a cytokine-induced memory-like natural killer (NK) cell—after a stem cell transplant can improve their chances of staying cancer-free. About 60 ad…

This trial tests a minimally invasive treatment that uses microwaves to destroy only the cancerous part of the prostate, leaving healthy tissue intact. The goal is to control the cancer while avoiding common side effects of full prostate removal, such as urine leakage and erectil…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…

This early-phase study is testing a combination of four drugs (belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone) in 14 people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The main goals are to check safety an…

This early-phase trial is testing whether adding the targeted drug venetoclax to standard chemotherapy can safely treat adults newly diagnosed with acute myeloid leukemia (AML). About 50 participants will receive the combination to find the best dose and see how many achieve remi…

This study was designed to test a drug called tolododekin alfa (ANK-101) given before surgery to kidney transplant recipients with high-risk skin cancer. The goal was to see if the drug could reduce the number of cancer cells in the removed tissue. However, the trial was withdraw…

This phase II trial tests whether adding the hormone-blocking drug relugolix to standard radiation therapy can slow cancer growth in men with prostate cancer that has spread to a few other spots in the body (oligometastatic). About 194 participants will receive either radiation a…

This phase 3 trial tests whether the drug pazopanib can delay or prevent kidney cancer from coming back in patients who have had all visible tumors removed by surgery. 129 adults with clear cell kidney cancer that had spread are randomly assigned to take either pazopanib or a pla…

This study tests a new long-acting injection called Debio 4228 for men with advanced prostate cancer. The goal is to lower testosterone levels to control the cancer. About 55 men will receive different doses to find the best one. This is not a cure, but a way to manage the diseas…

This phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…

This phase IV trial tests whether the drugs olaparib and bevacizumab, taken together after initial chemotherapy, can help prevent ovarian cancer from coming back in women with a specific genetic marker (HRD-positive). About 190 participants who have already responded to first-lin…

This early-stage study tests whether combining a radioactive drug (177Lu-PSMA-617) with precise radiation therapy (SBRT) is safe for men with hormone-sensitive prostate cancer that has spread to a few other spots in the body. The drug seeks out and attacks cancer cells, while the…

This early-stage trial is testing an experimental drug called APX005M in 32 children with brain tumors that have come back or are hard to treat, including a type of brain stem glioma. The drug works by activating the immune system to attack cancer cells. The main goals are to fin…

This phase 3 trial is testing whether the immunotherapy drug nivolumab (Opdivo) can prevent melanoma from coming back in people who have had their stage IIB/C melanoma completely removed. About 790 adults and children are randomly assigned to receive either nivolumab or a placebo…

This phase II trial is testing whether adding an experimental immunotherapy drug (retlirafusp alfa) to short-course radiation and standard chemotherapy can completely eliminate locally advanced rectal cancer before surgery. The study plans to enroll 44 adults aged 18-70 with stag…

This early study tests the safety of TheraSphere PCa, tiny radioactive glass beads injected into the prostate to treat localized prostate cancer. The trial involves 36 men with favorable intermediate-risk cancer and aims to find the maximum safe radiation dose. Researchers will m…

This study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…

This study compares a new three-drug combination (NABPLAGEM) against a standard two-drug chemo regimen for people with advanced pancreatic cancer that has spread and carries a BRCA or PALB2 gene mutation. The trial enrolls 10 participants whose cancer worsened after initial treat…

This phase 2 trial tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can improve outcomes for men with castration-resistant metastatic prostate cancer. About 60 participants will receive either one or two DNA vaccines along with pembrolizumab f…

This study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …

This study is for men whose prostate cancer has returned in the same area after they already had radiation and surgery. The researchers want to see if giving a very precise, high-dose radiation treatment (called SBRT) along with the diabetes drug metformin can safely control the …

This study tests whether taking enzalutamide for one year after standard treatment is practical for people with early-stage triple negative breast cancer that has androgen receptors. About 50 participants will take the drug and report on their quality of life. The main goal is to…

This study tests an experimental drug called LY2784544 in people with three types of blood cancers known as myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. The trial enrolls patients who have not responded to, cannot tolerate, or hav…

This early-stage study is testing a combination of two drugs, belantamab mafodotin and feladilimab, in 25 people with relapsed/refractory multiple myeloma who have already tried at least three other treatments. The main goal is to check the safety of the combination and find the …

This phase 3 study compares the experimental drug poziotinib to the standard chemotherapy docetaxel in 268 people with advanced non-small cell lung cancer that has a specific HER2 mutation. Participants must have already tried at least one prior treatment. The main goal is to see…

This study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…

This phase II trial investigates whether adding two immunotherapy drugs—tiragolumab and atezolizumab—to standard chemotherapy before and after surgery can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls 35 adults with stage II to IIIB dis…

This study compares two modern, wire-free methods for locating non-palpable breast lesions before surgery: radioguided occult lesion localization (ROLL) using a radioactive tracer, and magnetic seed localization. The goal is to see which technique more reliably achieves clear sur…

This phase 2 trial tests whether combining the targeted drug adagrasib with immunotherapy (pembrolizumab) and chemotherapy can shrink tumors or delay progression in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study enrolls adults wh…

This trial tests a sticky patch that releases fenretinide, a vitamin A derivative, directly onto precancerous spots inside the mouth. The goal is to see if the patch can shrink these lesions, reduce their severity under the microscope, and lower genetic changes linked to oral can…

This trial tests the drug savolitinib in children and adults whose brain tumors (medulloblastoma, high-grade glioma, or DIPG) have come back or not responded to treatment. The drug works by blocking an enzyme that some tumor cells need to grow. The study aims to find the safest d…

This phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This trial investigates whether using a special dye called indocyanine green (ICG) during surgery helps improve outcomes for people with stage III colorectal cancer. The dye makes lymph nodes and cancer tissue glow under a special camera, helping surgeons see and remove more of t…

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This phase 2 trial investigates whether adding a targeted radiation therapy called Lu-PSMA to the standard hormone drug enzalutamide can delay cancer progression in men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. Participants r…

This early-phase trial investigates whether itraconazole, a common antifungal medication, can reduce the risk of cancer in people with high-risk Barrett's esophagus who have already undergone endoscopic ablation. Barrett's esophagus often returns after treatment, increasing the c…

This phase 2 trial tests whether combining sacituzumab govitecan (a targeted antibody-drug conjugate) with pembrolizumab (an immunotherapy) before and after surgery can improve outcomes for people with resectable non-small cell lung cancer (NSCLC). Participants receive four cycle…

This study tests an experimental drug called CLN-081 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already received chemotherapy. The goal is to see if the drug is safe and can shrink tumors.

This phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular ca…

This phase 2 trial investigates whether a program of regular walking and a plant-based diet can lower aromatase levels in overweight postmenopausal women with hormone receptor-positive breast cancer who are already taking an aromatase inhibitor. Participants are randomly assigned…

This pilot study explores whether people with melanoma or non-small cell lung cancer that has spread to the brain can safely skip stereotactic radiosurgery (focused radiation) after having a brain tumor surgically removed. Instead of radiation, participants receive systemic thera…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This trial investigates whether combining two drugs—BCG and gemcitabine—can safely and effectively treat a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that has come back after previous BCG treatment. Participants receive BCG directly into the bladder …

This clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which c…

This phase 3 trial compares two chemotherapy approaches for people with germ cell tumors that have returned or not responded to initial treatment. One group receives standard-dose chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP). The other receives high-dose chemothe…

This phase 3 trial tests an experimental drug called SY-5007 in people with advanced non-small cell lung cancer that has a specific genetic change (RET fusion). The drug is a daily pill designed to block the cancer-driving RET protein. The study aims to see how well the drug shri…

This trial investigates whether adding proglumide, a drug that blocks cholecystokinin receptors, to standard chemotherapy can improve treatment for metastatic pancreatic cancer. About 30 adults with advanced pancreatic cancer will receive either proglumide or a placebo alongside …

This study compares two surgical methods for treating benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. The trial involves 140 men aged 50-80 with prostates of 80 mL or larger who are candidates for holmium laser enucleation. One group receives the …

This phase 2 trial tests a combination of three types of drugs—an immunotherapy (pembrolizumab), a targeted therapy (lenvatinib), and chemotherapy (pemetrexed plus cisplatin or carboplatin)—as a first treatment for people with advanced malignant pleural mesothelioma that cannot b…

This study investigates whether combining ACT001 (an oral drug) with pembrolizumab (an immunotherapy) can help people with recurrent glioblastoma, an aggressive brain cancer. Participants take the drugs before surgery to remove their tumor, allowing researchers to analyze how the…

This study compares two immunotherapy drugs—nivolumab alone versus nivolumab plus ipilimumab—in people with stage IV squamous cell lung cancer that has come back after previous treatment. Participants do not have a specific biomarker that would match them to another targeted ther…

This phase 2 trial tests whether eltrombopag, a drug already approved for other blood disorders, can improve blood cell counts in people with low-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have a mutation in the TET2 gene. Participants take…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…

This study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…

This study is testing a new way to detect prostate cancer by looking at cells in urine using a special imaging method. Researchers will collect urine samples from 675 men aged 50-75, including those with and without prostate cancer. The goal is to see if this simple test can accu…

This study looks at whether a special type of MRI, called multiparametric MRI, can more accurately determine the stage of prostate cancer in people who are newly diagnosed and planning surgery. The goal is to see if this imaging method helps doctors find aggressive cancers and ma…

This study looks at whether a special PET scan called Axumin can find prostate cancer that has returned after treatment, even when another common scan (PSMA PET) shows nothing. About 50 adults with rising PSA levels and a negative PSMA PET will get an Axumin scan. The goal is to …

This phase 2 trial tests whether a PET scan using a radioactive form of estrogen (FES) can predict how well endocrine therapy works in 99 women with newly diagnosed metastatic breast cancer. The scan lights up cancer cells that have estrogen receptors, helping doctors see if the …

This study aims to improve early detection of lung cancer in Asian women who have never smoked, a group at higher risk but not covered by standard screening guidelines. Participants receive up to three low-dose CT scans and a blood test designed to spot early signs of cancer. Res…

This study compares different HPV tests to find the best way to screen for cervical cancer in women living with HIV in Latin America. Over 1,000 participants will provide cervical, vaginal, and urine samples, plus undergo colposcopy and biopsies. The goal is to identify which tes…

This study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measur…

This study is testing two different imaging techniques—SPECT and PET—to see how well they can spot brain tumors called gliomas. Forty patients with primary or recurrent glioma will receive injections of two special tracers, then undergo scans to measure how much tracer is taken u…

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …

This study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Tho…

This study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal junction cancer from returning in the abdominal lining. The treatment uses drugs cisplatin and paclitaxel, which are heated and circulated in the b…

This study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either one HPV shot or a placebo to see if one dose is enough to prevent persistent HPV infections that can lead to …

This study compares two different doses of radiation aimed at the head (prophylactic cranial irradiation) to see which is better at preventing brain metastases in people with small cell lung cancer. Participants had their lung cancer diagnosed within the past year and have alread…

This phase 2 trial tests whether metformin, a widely used diabetes drug, can prevent oral cancer in 26 people with precancerous mouth lesions (leukoplakia or erythroplakia). Participants take metformin by mouth, and researchers check if the lesions shrink or disappear. The goal i…

This study tests whether a superoxide dismutase (SOD) spray can prevent severe radiation dermatitis (skin burns) in 140 head and neck cancer patients undergoing radiotherapy. The spray aims to neutralize free radicals that cause skin damage. If effective, it could reduce treatmen…

This study tests whether a superoxide dismutase (SOD) spray can prevent severe radiation dermatitis (skin burns) in 140 head and neck cancer patients undergoing radiotherapy. The spray aims to neutralize free radicals that cause skin damage. Researchers will check patients weekly…

This trial tests whether a program that combines educational materials with electronic health record reminders can increase HPV vaccination rates among children and young adults aged 11–26 in four Appalachian states. The goal is to improve vaccine uptake and ultimately prevent ce…

This study tests a 12-week program that combines a Fitbit activity tracker with personalized nutrition counseling from a dietitian for people recovering from pancreatic cancer surgery. Participants log their food intake and share data remotely, while completing surveys about thei…

This phase 2 trial is testing whether gradually increasing the dose of abemaciclib (a targeted cancer drug) can reduce side effects like diarrhea and help patients stick with treatment. It involves 90 people with early-stage, hormone receptor-positive, HER2-negative breast cancer…

This study looks at whether a mobile health program that combines physical activity tracking with mindfulness lessons can help breast cancer survivors become more active and feel better. About 304 women who finished cancer treatment within the past 5 years will take part in a 24-…

This study tests whether spiritual care sessions can improve spiritual wellbeing, reduce anxiety and depression, and increase satisfaction with care for people with stage IV lung or gastrointestinal cancer. About 36 adults will be randomly assigned to receive either spiritual car…

This study tests whether training the muscles you use to breathe can improve how long obese breast cancer survivors can exercise. Researchers will compare breathing exercises plus aerobic exercise to aerobic exercise alone in 78 women who finished treatment. The goal is to see if…

This study tests whether a headband with special semiconductors can help with memory and thinking problems (often called 'chemo brain') in people who have had breast or gynecologic cancer. About 50 participants will wear either the active headband or a placebo version for 18 hour…

This study tests a modified whole brain radiation technique that avoids a specific area of the brain called the corpus callosum genu, which is important for memory and thinking. The goal is to see if this approach helps preserve cognitive function in people with brain metastases …

This study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…

This phase 2 trial tests whether the drug RRx-001 can prevent severe oral mucositis (painful mouth sores) in 216 patients with head and neck cancer receiving standard chemoradiation. Patients are randomly assigned to receive RRx-001 or a placebo alongside their usual treatment. T…

This phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…

This study tests fezolinetant, a non-hormonal drug, for treating hot flashes in women with hormone-positive breast cancer who are on hormone therapy. About 984 women will take either fezolinetant or a placebo daily for a year. The goal is to see if fezolinetant reduces the number…

This phase 2 trial tests whether combining neurofeedback (a brain-wave training therapy) with the drug duloxetine can better relieve nerve pain caused by chemotherapy than either treatment alone. About 336 cancer survivors with persistent nerve pain will be randomly assigned to o…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This large study (ALCHEMIST) is screening over 8,000 people with early-stage non-small cell lung cancer to analyze the genes in their tumors. The goal is to identify genetic changes that could help doctors choose the best treatments, such as targeted therapies. Participants provi…

This observational study looks at whether combining a blood test that detects tumor DNA (ctDNA) with a new genetic risk score can better predict if endometrial cancer will come back after surgery. Researchers will follow 52 women who had a hysterectomy for endometrial cancer, col…

This study tracks a substance called 2-HG in the brains of people with a type of brain cancer (glioma) that has specific gene changes. By using special MRI scans over time, researchers hope to learn how and when these tumors become more aggressive. About 42 adults will have regul…

This study collects blood samples from people already in other NIH clinical trials who are having or are expected to have serious side effects from their drugs. The goal is to measure drug levels in the blood to better understand why side effects happen. Up to 100 participants ag…

This study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …

This study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…

This study tracks people who have had or will have a procedure called ablation to destroy kidney tumors. Researchers want to see how effective the procedure is and whether it improves patients' quality of life. Participants fill out questionnaires about their health and well-bein…

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find tumors that are hard to see on CT scans. About 3,900 adults with certain cancers or growths will have their biopsy or ablation procedure done using this smart needle. The g…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections fr…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study collects tumor tissue from 480 people with advanced biliary tract cancer in Taiwan to analyze their genetic makeup. The goal is to create a detailed map of genetic changes in this cancer, which could help identify potential targeted therapies. Participants are already …

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study aims to better understand fatigue by comparing people who have felt tired for more than a month with those who are not fatigued. Researchers will use questionnaires, physical tests, and optional brain scans to identify different types of fatigue. The goal is to gather …

This study collects blood and urine samples from 1,000 adults receiving radiation therapy for cancer. Researchers want to learn how radiation affects gene activity in white blood cells, damages red blood cells, and changes hormone levels. No new treatment is being tested—this is …

This study is not testing a new treatment. Instead, it follows people who already received experimental cell therapies (like growing immune cells from their tumors or blood) in earlier NCI Surgery Branch trials. The goal is to monitor their health for up to 15 years, as required …

This study follows over 32,000 people who helped clean up the 2010 Deepwater Horizon oil spill in the Gulf of Mexico. Researchers want to see if exposure to crude oil and chemical dispersants leads to long-term health problems like heart disease, cancer, or lung issues. Participa…

This study looks at how men with low-risk prostate cancer and their partners or close allies decide on treatment. Researchers want to understand how anxiety and uncertainty influence these choices. About 541 participants will fill out questionnaires about their feelings and prefe…

This study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…

This study looks at how surviving a pediatric brain tumor affects thinking and behavior. Researchers will use brain scans to examine brain structure in children who have completed treatment. The goal is to better understand the long-term cognitive challenges these survivors may f…

This study explores the personal and social changes people with pancreatic cancer face while undergoing chemotherapy. Researchers will survey 55 patients about physical, emotional, social, and spiritual shifts at the start of treatment and again 4-6 weeks later. The goal is to be…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study was designed to see if a combination of PET and MRI scans could detect early signs that treatment is working in people with stage IV HER2-positive breast cancer. The plan was to scan participants up to three times over six months and compare the images to standard meas…

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study investigates whether certain blood-based markers, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and the CA-125 elimination rate (KELIM score), can predict survival and surgical outcomes in women with advanced ovarian cancer. Researcher…

This study looks at how tiny genetic differences (called SNPs) in ALK-positive non-small cell lung cancer patients might influence how well the drug alectinib works and what side effects occur. Researchers will analyze DNA from 600 patients who have been taking alectinib for at l…

This study will observe 30 adults in Taiwan with relapsed or refractory multiple myeloma who are taking elranatamab as part of their regular care. Researchers will track how quickly the cancer responds, how long the response lasts, and overall survival. The goal is to understand …

This study tests whether a virtual training and peer-mentoring program called Project ECHO can help healthcare providers in Ethiopia improve cervical cancer screening and treatment for women living with HIV. The program focuses on using HPV self-sampling, a simpler screening meth…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at t…

This study tests a special PET scan (FES) that tracks estrogen receptors in breast cancer tumors. Researchers want to see if changes in scan results before, during, and after hormone therapy can show how well the treatment is working. The study involves adults with estrogen recep…

This study looks at whether a large database of patient health records (Truveta) can be used as a control group for a glioblastoma drug called BPM31510. Glioblastoma is a fast-growing brain tumor, and it is hard to run traditional placebo-controlled trials because the disease is …

This study looks at whether a genetic test can predict who will develop Paget's disease of the bone, a condition that can cause pain, deformity, and hearing loss. Researchers are studying 135 people aged 45 and older who have a parent or sibling with Paget's but do not have the d…

This study tracks how 150 patients in Belgium use the drug cabozantinib (Cabometyx), alone or with nivolumab, for advanced or metastatic kidney cancer. It looks at real-world dosing, treatment changes, and quality of life. The goal is to understand how these treatments are actual…

This study looks at how breast cancer treatment affects quality of life in women of different ages. Researchers are asking 650 women recently diagnosed with early-stage breast cancer to fill out questionnaires about their physical and emotional well-being. The goal is to understa…

This study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…

This study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …

This study tests whether a simple mathematical formula, applied to routine CT scans, can accurately predict the size of a bone defect that will be created during surgery to remove a bone tumor. Accurate prediction could help surgeons select the right-sized donor bone graft before…

This study observes 224 adults with advanced or metastatic kidney cancer who are taking cabozantinib alone or with nivolumab as their first treatment. Researchers track how often doses are reduced, paused, or stopped due to side effects in everyday medical practice. The goal is t…

This study looks at whether combining a genetic test called the Genomic Prostate Score (GPS) with MRI scans can help doctors better choose men with prostate cancer for focal therapy, which treats only the cancerous part of the prostate. Researchers will analyze data and tissue sa…

This study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…

The PRECISION trial is studying whether women with a specific type of early-stage breast cancer can safely avoid radiation therapy after having a lumpectomy. Participants have tumors that are small, hormone receptor-positive, HER2-negative, and low-grade. A gene test called Prosi…

This study collects extra tissue samples from 200 people with advanced non-small cell lung cancer during routine biopsies. The goal is to train and validate a new diagnostic platform called Cybrid, which aims to predict how well a patient's tumor will respond to immunotherapy. Th…

This study explores how much energy people with incurable cancer actually use, compared to standard formulas. Researchers will measure resting energy expenditure using a special device and track survival over time. The goal is to improve nutritional care for these patients.

This study aims to identify which of four French-validated questionnaires is most suitable for assessing sexual function in women who have had surgery for rectal or recto-sigmoid cancer. Researchers will ask 50 women to complete all four questionnaires and rank their preferences.…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…

This study looks at whether a blood test that measures tumor DNA (ctDNA) can predict how well chemotherapy is working in people with advanced pancreatic cancer. Researchers will compare the blood test results with CT scans taken before and two months after starting treatment. The…

This study is creating a biobank—a collection of blood, tumor tissue, and health data—from 500 people with pancreatic cancer. Researchers want to learn why some groups are affected more than others and how cachexia (severe weight loss) develops. Participants donate samples and fi…

This study follows 810 young women aged 18-45 with early-stage breast cancer to understand how treatment affects their menstrual cycles and quality of life. Participants complete questionnaires every six months for up to 42 months. The goal is to identify factors that lead to ear…

This study planned to test whether adding low-dose radiation to standard high-dose radiation could trigger an 'abscopal effect' – where untreated tumors also shrink. It was designed for adults with metastatic solid tumors. However, the study was withdrawn before any patients were…

This study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …

This study tests whether offering a blood test (cell free DNA) alongside standard stool tests and colonoscopy increases colorectal cancer screening rates among people who are not up-to-date with screening. The trial enrolls 340 adults aged 45-75 at a health center serving low-inc…

This study is not testing a new treatment. Instead, it observes how 400 men with advanced prostate cancer are actually treated in Russia, and looks for biomarkers in their tumor samples. The goal is to understand current practices and identify factors that might influence outcome…

This Phase 2 trial tests whether dichloroacetate (DCA), a drug that affects cell energy use, can alter tumor metabolism in people with recurrent glioblastoma. Forty patients scheduled for surgery will either receive DCA or no drug for one week before their operation. Researchers …

This study looks at whether teaching stem cell transplant survivors and their primary care doctors about skin cancer screening can lead to earlier detection. Participants receive educational materials and some doctors get a dermatoscope (a magnifying lens). The goal is to see if …

This study investigates how the brain processes speech sounds to understand language. Researchers will record brain activity from people with epilepsy or brain tumors who already have electrodes implanted for medical reasons. Participants listen to short speech sounds while their…

This study looks at why people who have had an organ transplant are more likely to get cancer. Researchers will combine existing health records from over 85,000 transplant patients in England to track cancer cases and deaths. The goal is to better understand risks and improve car…

This study collects blood and tissue samples from 1,000 adults with Barrett's esophagus or esophageal cancer during their routine endoscopy. The goal is to build a biorepository that links clinical data with specimens, enabling future research into these conditions. Participants …

This study is looking for 50 adults with soft tissue sarcoma to see if a blood test can detect tumor DNA (ctDNA) as well as a standard tissue biopsy. Currently, doctors need to take a piece of the tumor to diagnose and monitor sarcoma, which can be risky and hard to do. By compar…

This study looks at prostate cancer tissue from men undergoing prostate removal surgery to find cells that may be especially aggressive and resistant to treatment. Researchers give a special dye (pimonidazole) before surgery to mark oxygen-starved areas, then analyze the removed …

This study looks back at 1,400 women who had breast-conserving surgery for non-palpable breast lesions. It compares two methods used to find the lesion during surgery: injecting a radioactive substance (ROLL) or placing a tiny magnetic seed. The goal is to see which technique lea…

This study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolum…

This study looks at whether surgery for early-stage cervical cancer causes tumor cells to enter the bloodstream, which might explain higher recurrence rates seen with certain surgical methods. Researchers will take blood samples from 20 women during their operation to detect circ…

This study looks at how patients with advanced blood cancers (like acute myeloid leukemia) who are not eligible for a cure, along with their nurses and doctors, feel about the benefits of blood transfusions. Researchers will give questionnaires before each transfusion to compare …

This study investigates whether a simple blood test can help diagnose and monitor low-grade gliomas, a type of slow-growing brain tumor. Researchers will collect blood samples from 50 patients undergoing brain surgery to look for circulating tumor cells and other markers. The goa…

This study is developing an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing a more severe form called castration-resistant prostate cancer. The AI will analyze MRI images, biopsy slides, and clinical data from…

This study checks the eye health of people with breast cancer using standard tests like vision charts, eye exams, and scans. The goal is to spot any vision changes or eye damage that might happen during cancer treatment. About 160 participants will be followed to understand how b…

This study looks at genetic changes in blood and tumor samples from women with advanced hormone receptor-positive, HER2-negative breast cancer who are being treated with palbociclib and endocrine therapy. By comparing genetic material from the cancer tissue with that found in the…

This study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …